AP NEWS
Click to copy
Press release content from PR.com. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from PR.com
Press release content from PR.com. The AP news staff was not involved in its creation.

Vesalio Obtains Additional CE Approval for New Products, NeVa Clinical Data Published

VesalioMay 22, 2019

Nashville, TN, May 22, 2019 --( PR.com )-- Vesalio announces it has obtained its second CE mark approval spanning multiple new NeVa™ neurothrombectomy product designs and technology. The new generation NeVa devices expand on the Drop Zone™ and Smart Marker™ technologies while also introducing first-to-market features such as a distal filter. A controlled launch of the newly approved products will begin in June in Europe with expected full commercial release in the fourth quarter of 2019.

Vesalio also reports a publication entitled, “Mechanical thrombectomy with a novel stent retriever with multifunctional zones: Initial clinical experience with the NeVa™ thrombectomy device,” was recently published in the May 2019 issue of Journal of Neuroradiology. NeVa was utilized as a first line thrombectomy device by 4 stroke centers in Switzerland and Spain. NeVa First Pass recanalization results were 63% TICI 2b/3. Final revascularization scores were 93% TICI 2b/3 with 1.7 average passes and 70% clot incorporation in the NeVa basket.

“We are excited to be granted our second CE Mark approval. Our new technology appears very promising based on early feedback from several physician KOLs. The approval combined with positive clinical results recently published from our first generation NeVa devices has led to an increased market interest in NeVa. We are encouraged by our growth as we are nearing our first anniversary of commercialization. The expansion of the NeVa platform should provide an excellent opportunity for Vesalio to gain additional market share,” commented Steve Rybka, CEO.

About Vesalio, LLC

Founded in 2013, Vesalio is a privately held medical device company focused on advancing technology needed to improve outcomes in stroke treatment. The Company’s proprietary NeVa™ platform was designed to achieve repeatable and superior clinical outcomes by providing physicians “first pass” success in effectively capturing and retaining a neurovascular clot inside the device.

For further information, visit www.vesalio.com or email info@vesalio.com. NeVa trademarks and patents are the property of Vesalio.

Contact Information:

Vesalio

William von Brendel

858-335-5790

Contact via Email

www.vesalio.com

Read the full story here: Vesalio Obtains Additional CE Approval for New Products, NeVa Clinical Data Published

Press Release Distributed by PR.com

All contents © copyright 2019 The Associated Press. All rights reserved.